Research and Development Expenses Breakdown: Pfizer Inc. vs GSK plc

Pfizer vs GSK: A Decade of R&D Investment

__timestamp	GSK plc	Pfizer Inc.
Wednesday, January 1, 2014	3450000000	8393000000
Thursday, January 1, 2015	3560000000	7690000000
Friday, January 1, 2016	3628000000	7872000000
Sunday, January 1, 2017	4476000000	7657000000
Monday, January 1, 2018	3893000000	8006000000
Tuesday, January 1, 2019	4568000000	8650000000
Wednesday, January 1, 2020	5098000000	9405000000
Friday, January 1, 2021	5278000000	13829000000
Saturday, January 1, 2022	5488000000	11428000000
Sunday, January 1, 2023	6223000000	10679000000
Monday, January 1, 2024		10930000000

Igniting the spark of knowledge

A Decade of Innovation: Pfizer Inc. vs GSK plc

In the ever-evolving pharmaceutical landscape, research and development (R&D) are the lifeblood of innovation. Over the past decade, Pfizer Inc. and GSK plc have been at the forefront, investing heavily in R&D to drive breakthroughs in healthcare. From 2014 to 2023, Pfizer consistently outpaced GSK in R&D spending, with an average annual investment nearly double that of GSK. Notably, Pfizer's R&D expenses peaked in 2021, reaching a staggering 13.8 billion dollars, reflecting a 65% increase from 2014. Meanwhile, GSK's R&D spending showed a steady upward trend, culminating in a 6.2 billion dollar investment in 2023, marking an 80% rise over the same period. This commitment to innovation underscores the critical role of R&D in addressing global health challenges and advancing medical science.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025